We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Policy & Advocacy

Genentech participates in the political process in a constructive, proactive, transparent and responsible manner. Through our policy and advocacy efforts, we engage with policymakers, trade associations, patient groups, think tanks and other key stakeholders to advance policies that support a more socially-conscious society as well as a more equitable, accessible, and affordable healthcare system for patients.

Our advocacy efforts are grounded in our commitment to putting all patients at the center of the work we do. We strive for policies that strike the right balance between ensuring people can access, afford and benefit from the medicines they need and investing in future scientific breakthroughs and therapeutic advancements.

Our Work

Public Policy and Political Engagement

At Genentech, we believe diverse perspectives and stakeholder collaboration are essential to solving today’s most pressing healthcare challenges and we’re committed to being part of the solution. A critical component of our work is advocating for state and federal policies that encourage scientific innovation and ensure patient access to our life-saving medicines. We actively participate in the political process, and our engagement enables us to inform policymakers and other stakeholders about the impact of key issues on our business and most importantly, the patients we serve. We are committed to responsible interactions with government candidates and officials that are conducted in a legal and ethical manner consistent with applicable laws and Genentech policies.

To learn more about our corporate mission and values, as well as our Code of Conduct, please click here.

Political Giving through the Genentech Political Action Committee

Central to our mission at Genentech is our belief that inclusivity and the acceptance of broad perspectives and opinions will allow us to break down existing barriers in the pursuit of innovation and progress. One way employees can participate in the political process is through Genentech’s nonpartisan, nonprofit Political Action Committee (PAC). The Genentech PAC is funded solely by voluntary contributions from eligible employees and supports state and federal candidates for office who share our belief in the importance of scientific innovation and ensuring patients have access to the medicines they need. Genentech’s PAC, or GenenPAC, is governed by an internal Board of Directors and is committed to complying with FEC rules and regulations. GenenPAC contributions are made publicly available and reported to the Federal Election Commission, as required by law.

The Genentech PAC strives for political balance in our political giving, supporting both Republicans and Democrats.

Trade and Industry Associations

Genentech is a member of several trade and industry associations that represent the biopharmaceutical industry and business community in policy discussions. Together we help drive consensus on policy, business, and Diversity, Equity and Inclusion priorities, advocating for solutions that will benefit patients, our healthcare system and society as a whole.

Genentech’s association engagement includes Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Industry Organization (BIO), California Life Sciences Association (CLSA), U.S. Chamber of Commerce (USCC), and the National Association of Manufacturers (NAM), among others.

Patient Advocacy and Stakeholder Engagement

Our commitment to fostering sustainable relationships with patient advocacy organizations, patients, care partners, and other key stakeholders helps Genentech support the patients we serve holistically – we're more than just the medicine.

More than 25 years later, Genentech continues to lead the industry in prioritizing engagement with patient advocacy organizations, collaborating with them early and often throughout the lifecycle of our drug development process and across key issues. Learn more about how we engage with patients here.

  • >400 relationships with patient advocacy organizations
  • 50 disease areas included in our advocacy efforts

Our Focus

Genentech is dedicated to working with stakeholders to advocate for policies that address barriers to patient access, create a more equitable and affordable healthcare ecosystem, and pave the way for the innovative treatments our scientists work tirelessly to discover every day.

Pricing

Genentech has a long-standing pricing philosophy that is designed to strike a balance between ensuring patients have rapid, broad and sustainable access to our medicines, while at the same time preserving our ability to invest in future scientific innovations.

Learn More
Diversity, Equity & Inclusion

We’re committed to fostering belonging for our people, advancing inclusive research and health equity for all patients, and investing in transformative partnerships that strengthen DE&I across healthcare, education and within all communities.

Learn More
Advancing Inclusive Research

We are deeply committed to addressing barriers to clinical trial participation and advancing inclusive research.

Learn More
Personalized Healthcare

Profound advances in science, holistic approaches to data and innovative technology are giving us new tools to help us improve every aspect of the patient experience and drive better health outcomes.

Learn More
Sustainability

We believe that a healthy future for our global community starts in our own backyard. We view every decision we make through the lens of its potential impact on our people and our planet.

Learn More
Our Response to COVID-19

Learn more about our commitment to help address the impacts of COVID-19 in our communities and across the U.S.

Learn More

Our Position

We are dedicated to understanding and communicating the real-world impact our policies have on our patients and to partnering with stakeholders who help us power positive change. Read our editorials and statements on key policy issues.

We believe it is time to apply the same bold thinking that’s behind our life-changing science to our policy solutions and to our pricing philosophy. This means finding a solution that truly improves upon the healthcare system we have in the United States.

Fritz Bittenbender, Senior Vice President, Access & External Affairs, Genentech, A Member of the Roche Group
Read the full article